

Electronic supporting information for

Tuning the spin-transition properties of pyrene decorated 2,6-Bispyrazolypyridine based Fe(II) complexes

Rodrigo González-Prieto,^a Benoit Fleury,^a Frank Schramm,^a Giorgio Zoppellaro,^{a,b} Rajadurai Chandrasekar,^{a,c} Olaf Fuhr,^a Sergei Lebedkin,^a Manfred Kappes,^a and Mario Ruben^{*a,d}

^a Karlsruhe Institute of Technology (KIT), Institute of Nanotechnology, Hermann-von-Helmholtz-Platz 1, 76344 Eggenstein-Leopoldshafen, Germany. ^bDepartment of Molecular Biosciences, University of Oslo, PO Box 1041 Blindern, Oslo NO-0316, Norway. ^cSchool of Chemistry, University of Hyderabad, Prof. C. R. Rao Road, Gachhi Bowli, Hyderabad – 500 046, India. ^dInstitut de Physique et Chimie des Matériaux de Strasbourg (IPCMS), 23 rue de Loess, BP55, 67034 Strasbourg cedex 2, France. Fax: +49 (0) 7247 82 8976; Tel: +49 7247 82 6781; E-mail: mario.ruben@kit.edu

Table S1: Crystallographic and refinement data of **1**

Compound	1
Empirical formula	C ₅₄ H ₃₄ Cl ₂ FeN ₁₀ O ₈
Formula weight	1077.66
Crystal system	monoclinic
Space group	C2/c
a/pm	1518.0(3)
b/pm	836.9(2)
c/pm	3650.5(7)
β/°	100.69(3)
V/10 ⁶ pm ³	4557(2)
Z	4
μ/mm ⁻¹	0.522
Density/g cm ⁻³	1.571
F(000)	2208
Reflections collected	6333
Independent reflections	3259 [R _{int} = 0.0484]
Indp. reflections with F ₀ >4σ(F ₀)	2169
Restraints / parameter	0 / 408
GooF on F ²	0.932
R ₁ , wR ₂ [I>2σ(I)]	0.0528, 0.1195
R ₁ , wR ₂ (all data)	0.0841, 0.1328
Largest difference peak, hole/e Å ⁻³	0.282 / -0.471




Figure S1. ^1H NMR spectrum of 2,6-di(1H-pyrazol-1-yl)-4-(pyren-1-yl)pyridine (**L1**) in CDCl_3 .




Figure S2. ^{13}C NMR spectrum of 2,6-di(1H-pyrazol-1-yl)-4-(pyren-1-yl)pyridine (**L1**) in CDCl_3 .




Figure S3. ESI-TOF mass spectrum of 2,6-di(1H-pyrazol-1-yl)-4-(pyren-1-yl)pyridine (**L1**). Experimental (up) and simulated (down) isotopic distributions for the most intense peak; **L1**+H⁺; are shown in the inset.




Figure S4. ^1H NMR spectrum of 4-(4'-hydroxymethylphenyl)-2,6-bis(pyrazol-1-yl)pyridine in CDCl_3 .




Figure S5. ^{13}C NMR spectrum of 4-(4'-hydroxymethylphenyl)-2,6-bis(pyrazol-1-yl)pyridine in CDCl_3 .




Figure S6a. MALDI mass spectrum of 4-(4'-hydroxymethylphenyl)-2,6-bis(pyrazol-1-yl)pyridine.




Figure S6b. Experimental (up) and simulated (down) isotopic distributions of the most intense peak; $M+H^+$.




Figure S7. ^1H NMR spectrum of 4-(2,6-di(1H-pyrazol-1-yl)pyridin-4-yl)benzyl 4-(pyren-1-yl)butanoate (**L2**) in CDCl_3 .




Figure S8. ^{13}C NMR spectrum of 4-(2,6-di(1H-pyrazol-1-yl)pyridin-4-yl)benzyl 4-(pyren-1-yl)butanoate (**L2**) in CDCl_3 .




Figure S9. ESI-TOF mass spectrum of 4-(2,6-di(1H-pyrazol-1-yl)pyridin-4-yl)benzyl 4-(pyren-1-yl)butanoate (**L2**). Experimental (up) and simulated (down) isotopic distributions for the most intense peak; **L2**+H⁺; are shown in the inset.




Figure S10. (a) ^1H NMR spectrum of $[\text{Fe}(\text{L}1)_2](\text{ClO}_4)_2$ (**1**) in CD_3CN . Insets (b) and (c) show enlarged zones of the whole spectrum.




Figure S11. ESI-TOF spectrum of $[\text{Fe}(\text{L}1)_2](\text{ClO}_4)_2$ (**1**). Experimental (up) and simulated (down) isotopic distributions for the most intense peak; M^{2+} ; are shown in the inset.




Figure S12. FT-IR spectrum of $[\text{Fe}(\text{L}1)_2](\text{ClO}_4)_2$ (**1**).




Figure S13. $1/\chi_M$ versus T plot for $[\text{Fe}(\text{L}1)_2](\text{ClO}_4)_2$ (**1**).




Figure S14. (a) ^1H NMR spectrum of $[\text{Fe}(\text{L}2)_2](\text{ClO}_4)_2$ (**2**) in CD_3CN . Insets (b) and (c) show enlarged zones of the whole spectrum.




Figure S15. ESI-TOF spectrum of $[\text{Fe}(\text{L}2)_2](\text{ClO}_4)_2$ (**2**). Experimental (up) and simulated (down) isotopic distributions for the most intense peak; M^{2+} ; are shown in the inset.




Figure S16. FT-IR spectrum of [Fe(L2)₂](ClO₄)₂ (**2**).




Figure S17. (a) ^1H NMR spectrum of $[\text{Fe}(\text{L}2)_2](\text{BF}_4)_2 \cdot \text{CH}_3\text{CN} \cdot \text{H}_2\text{O}$ (**3**) in CD_3CN . Insets (b) and (c) show enlarged zones of the whole spectrum.




Figure S18. ESI-TOF spectrum of $[\text{Fe}(\text{L}2)_2](\text{BF}_4)_2 \cdot \text{CH}_3\text{CN} \cdot \text{H}_2\text{O}$ (**3**). Experimental (up) and simulated (down) isotopic distributions for the most intense peak; M^{2+} ; are shown in the inset.




Figure S19. Emission spectra of compound **3** (polycrystalline) excited at 270 nm at different temperatures. The half-bandwidths of the excitation and emission monochromators corresponded to 4 nm




Figure S20. Normalized emission intensity of polycrystalline pyrene butyric acid as a function of the temperature. The excitation and emission wavelengths are 300 and 528 nm, respectively.